Bolivia's medicines regulator, created in 2016. It registers medicines, authorises clinical trials, runs the national pharmacovigilance centre and keeps the national essential medicines list that guides public purchasing.
AGEMED was created on 21 September 2016 by Decreto Supremo 2905 as a deconcentrated body of the Ministry of Health with administrative, financial, legal and technical independence. Its own history traces the function to a national chemical and pharmaceutical service founded in 1937, later the Dirección de Medicamentos y Tecnología en Salud (DINAMED) and, from 2006, the Unidad de Medicamentos y Tecnología en Salud (UNIMED); that history comes from the agency's own site, whose history page could not be re-read on 17 November 2026. Its offices are in Sopocachi, La Paz; the coordinates are approximate.
Its departments cover marketing authorisation, inspection and post-market control, health technology assessment and rational use, and the national pharmacovigilance centre, and its quality control laboratory, CONCAMYT, works to WHO good practices for pharmaceutical laboratories. It keeps the Lista Nacional de Medicamentos Esenciales (LINAME); the 2026 to 2027 list, approved by Ministerial Resolution 0121, includes 41 antineoplastic medicines under ATC group L01, among them trastuzumab, pertuzumab, rituximab, imatinib and dasatinib, and 10 hormone treatments under L02.
The clinical trial norm it publishes gives the authority 60 calendar days to decide on an application. Its list of registered trials holds studies of Chagas disease, leishmaniasis and COVID-19 and none of cancer. WHO's August 2026 list of regulators at maturity level 3 or 4 does not include Bolivia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/